Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open …

R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - thelancet.com
Background Encorafenib plus binimetinib and encorafenib alone improved progression-free
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …
被引用次数：596 相关文章 所有 12 个版本
[PDF] uzh.ch

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase …

R Dummer, PA Ascierto, HJ Gogas, A Arance… - The Lancet …, 2018 - thelancet.com
Summary Background Combined BRAF-MEK inhibitor therapy is the standard of care for
BRAF V600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor …
被引用次数：1008 相关文章 所有 12 个版本
[PDF] ascopubs.org

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF …

R Dummer, KT Flaherty, C Robert, A Arance… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Combination treatment with BRAF and MEK inhibitors has demonstrated benefits
on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the …
被引用次数：91 相关文章 所有 9 个版本
[HTML] sciencedirect.com

[HTML][HTML] Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or …

PA Ascierto, R Dummer, HJ Gogas, KT Flaherty… - European Journal of …, 2020 - Elsevier
Background BRAF/MEK inhibitor combinations are established treatments for BRAF V600–
mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and …
被引用次数：192 相关文章 所有 12 个版本
[HTML] sciencedirect.com

[HTML][HTML] Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

HJ Gogas, KT Flaherty, R Dummer, PA Ascierto… - European Journal of …, 2019 - Elsevier
Background Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK
inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic …
被引用次数：91 相关文章 所有 12 个版本

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations

C Trojaniello, L Festino, V Vanella… - Expert review of clinical …, 2019 - Taylor & Francis
Introduction Combination treatment with a BRAF inhibitor and MEK inhibitor is the standard
of care for patients with advanced BRAF V600 mutation-positive melanoma. With the …
被引用次数：59 相关文章 所有 3 个版本
[HTML] sciencedirect.com

[HTML][HTML] Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and …

P Corrie, N Meyer, R Berardi, M Guidoboni… - Cancer Treatment …, 2022 - Elsevier
Background The objective of this study was to estimate the relative efficacy and safety of
targeted therapies for the treatment of metastatic melanoma using a network meta-analysis …
被引用次数：17 相关文章 所有 9 个版本
[HTML] lww.com

[HTML][HTML] Development of encorafenib for BRAF-mutated advanced melanoma

P Koelblinger, O Thuerigen… - Current opinion in …, 2018 - journals.lww.com
Combination therapy with BRAF and MEKi has evolved as a standard of care in the
treatment of locally advanced or metastatic BRAF V600-mutated melanoma. Despite …
被引用次数：163 相关文章 所有 12 个版本
[PDF] uzh.ch

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

JP Delord, C Robert, M Nyakas, GA McArthur… - Clinical Cancer …, 2017 - AACR
Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that
is distinct from that of other clinically active BRAFis. We evaluated encorafenib in a phase I …
被引用次数：180 相关文章 所有 9 个版本

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150) …

PA Ascierto, D Stroyakovskiy, H Gogas… - The Lancet …, 2023 - thelancet.com
Background Primary analysis of the phase 3 IMspire150 study showed improved
investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib …
被引用次数：52 相关文章 所有 5 个版本